Online Health Care Data Sources

from Brookings Topics – Health at http://brook.gs/11VteET on November 25, 2014 at 05:00AM This is a preliminary scan of publically available online health care datasets, transparency websites and tools, gathered from expert recommendations and intensive review. Though this list is not exhaustive, we have attempted to include the most relevant sources for the purposes of […]

CHEPA seminar looks at use of Malawi’s public health system to fight HIV transmission

from NewsFeed at http://bit.ly/11VHQEo on November 25, 2014 at 07:26PM Applying health systems research to prevent HIV transmission from mother to child in an impoverished country will be discussed on Dec. 2 by officials from Dignitas International (DI) a Canadian medical humanitarian non-government organization (NGO) that supports the Ministry of Health (MOH) in Malawi in the […]

Online Health Care Data Sources

from Brookings Topics – Health at http://brook.gs/11VteET on November 25, 2014 at 05:00AM This is a preliminary scan of publically available online health care datasets, transparency websites and tools, gathered from expert recommendations and intensive review. Though this list is not exhaustive, we have attempted to include the most relevant sources for the purposes of […]

Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?

from Latest Results for PharmacoEconomics at http://bit.ly/15pkBVu on November 26, 2014 Abstract In Canada, there are two separate review processes for the public reimbursement of drugs: one for cancer drugs (originally called the Joint Oncology Drug Review [JODR] and now called the pan-Canadian Oncology Drug Review [pCODR]) and one for drugs in all other disease […]

Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective

from Latest Results for PharmacoEconomics at http://bit.ly/1zqRl9L on November 26, 2014 Abstract The National Institute for Health and Care Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical and cost-effectiveness of alteplase for the prevention of strokes within a 0–4.5 h window. The comparator was standard medical and supportive […]

Targeting drug development

from The Incidental Economist at http://bit.ly/15niykM on November 25, 2014 at 03:00PM Muthiah Vaduganathan and Vinay Prasad in a JAMA Viewpoint: From a pragmatic standpoint, drug development programs conducted in broad populations poorly prioritize which patients should start therapy first. If provided regardless of risk, expensive new first-in-class agents may overwhelm health care budgets. In hepatitis C management, novel […]

Regulating innovation

from The Incidental Economist at http://bit.ly/1FnQmZV on November 25, 2014 at 02:06PM Paul Demko reports: [CMS] wants to require insurers to establish “pharmacy and therapeutics” committees that would meet at least four times a year to review drug formularies. […] If an insurer rejects a customer’s request, under the proposed rule the individual would have the […]

Is Pay for Performance Corrupting Medicine?

from The Incidental Economist at http://bit.ly/1rayzV5 on November 25, 2014 at 02:00PM Pamela Hartzband and Jerome Groopman have a recent New York Times editorial arguing that quality incentives for doctors are corrupting medicine: [F]inancial forces largely hidden from the public are beginning to corrupt care and undermine the bond of trust between doctors and patients. Insurers, hospital networks and regulatory […]

Just published: empirical study examining public preferences regarding end of life treatments

from News at http://bit.ly/1v9DZxQ on November 24, 2014 at 04:12PM Just published: empirical study examining public preferences regarding end of life treatments Monday, 24 November 2014 Just published in Social Science & Medicine [open access] is a social preference study by OHE’s Koonal Shah and the University of Sheffield’s Aki Tsuchiya and Allan Wailoo. The study […]

Obesity in the Context of Aging: Quality of Life Considerations

from Latest Results for PharmacoEconomics at http://bit.ly/11PsjWs on November 25, 2014 Abstract The progressive increase in the prevalence of obesity and aging in the population is resulting in increased healthcare and disability spending. The burden of obesity is particularly relevant in old age, due to accumulating co-morbidities and changes in body composition. Sarcopenic obesity, a […]

Munchausen Syndrome by Proxy exists, and we’re terrible at dealing with it

from The Incidental Economist at http://bit.ly/1FjHu7t on November 24, 2014 at 03:00PM As a resident, I saw more than one case of suspected Munchausen Syndrome by Proxy. Munchausen Syndrome, named after Baron Munchausen who supposedly told many tall tales about himself, is a mental disorder where a patient makes up symptoms or problems in order to get […]

THE VALUE OF GENETIC DIVINATION – STATED PREFERENCES FOR PERSONALIZED INFORMATION FOR REDUCING MORTALITY RISKS

from ISPOR News & Press Releases at http://bit.ly/15e446S on November 24, 2014 at 02:11PM Durham, NC, USA – The advent of genetic testing provides individuals and health care systems the opportunity to acquire information about predispositions to cancers and other diseases.  Whether this information is useful depends on the existence of efficacious health interventions… Read […]